Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Pharma & Biotech
Pharma & Biotech
Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Pharma & Biotech
Amgen acquires Dark Blue Therapeutics to expand targeted AML degradation strategy
Amgen has acquired United Kingdom-based Dark Blue Therapeutics Ltd. in a deal valued at up to $840 million, adding a first-in-class preclinical asset to its early oncology pipeline. The investigational small molecule, designed to degrade MLLT1 and MLLT3 proteins, targets transcriptional dependencies in acute myeloid leukemia. With preclinical data suggesting anti-leukemic activity and mechanistic differentiation,
Pharma & Biotech
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
Pharma & Biotech
Amgen adds Aimovig and Amjevita to TrumpRx platform in latest move to defuse U.S. pricing pressure
Amgen has expanded its direct-to-patient program, AmgenNow, to include Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto), each now available at a flat monthly price of $299 for eligible U.S. patients. This development forms part of Amgen’s broader agreement with the Trump Administration, satisfying conditions laid out in the President’s July 31 policy letter and positioning the company
Features & Analysis
Is twice-yearly dosing the future of autoimmune care? Inside Amgen’s UPLIZNA playbook for chronic neurology
When Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration had approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis (gMG), the industry’s attention snapped not just to the therapy’s mechanism but to its twice-yearly maintenance schedule. For patients, this marks a seismic shift away from the exhausting cycle of daily oral immunosuppressants
Pharma & Biotech
Can B-cell depletion change how we treat generalized myasthenia gravis?
Amgen has received approval from the United States Food and Drug Administration for Uplizna (inebilizumab-cdon) to treat adults with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive. The greenlight makes Uplizna the first and only CD19-targeted B cell therapy approved for this patient population, introducing a twice-yearly dosing regimen